Is Novavax Stock a Good Bet on Coronavirus Vaccines?
If you look only at Novavax's (NASDAQ: NVAX) share performance last year, you would probably hesitate to buy the stock today. The biotech company soared more than 2,000% in 2020. Investors were busy scooping up shares as the company advanced its coronavirus vaccine candidate and won more than $1.6 billion from the U.S. government to fund its development.
Now you might be thinking that its growth story is over. Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have both brought vaccines to market, and the U.S. government bought enough of them to immunize the whole country. What could possibly be left for Novavax? Let's take a look at where the company stands right now -- and whether it's still a good bet on vaccines.
Image source: Getty Images.
Source Fool.com
